A Study to Assess Nicotine Uptake From Electronic Nicotine Delivery System Products
- Sponsor
- RAI Services Company
- Study ID
- NCT07739797
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Smoking ( Cigarette)
- Smoking Behaviors
- Tobacco Use
Eligibility Criteria
- Sex
- ALL
- Age
- 21 Years - 60 Years
- Healthy Volunteers
- Accepted
Interventions
- Golden Tobacco Chill 5% (4) 6.5W — OTHERGolden Tobacco Chill 5% (4) 6.5W
- Glacier Menthol 5% (4) 6.5W — OTHERGlacier Menthol 5% (4) 6.5W
- Fresh Mint 5% (4) 6.5W — OTHERFresh Mint 5% (4) 6.5W
- Fresh Mint 5% (4) 4.5W — OTHERFresh Mint 5% (4) 4.5W
- Fresh Mint 5% (3) 6.5W — OTHERFresh Mint 5% (3) 6.5W
- Fresh Mint 5% (3) 5.5W — OTHERFresh Mint 5% (3) 5.5W
- Fresh Mint 5% (2) 6.5W — OTHERFresh Mint 5% (2) 6.5W
- Usual Brand Cigarette — OTHERUsual Brand Cigarette
Study Details
This will be a randomized, open-label, 8-way crossover, single-site study designed to evaluate elements of abuse liability (AL), including subjective effects and physiological measures (pharmacodynamics \[PD\]), and plasma nicotine uptake (pharmacokinetics \[PK\]) during and following ad libitum use of electronic nicotine delivery system (ENDS) investigational products (IPs). The study will be conducted in a confinement setting among generally healthy adult smokers of combustible cigarettes and dual users of cigarettes and ENDS products.
Key Dates
- First listed
- Jul 31, 2026
- Start date
- Oct 1, 2026
- Status verified
- Jul 2026
- Primary completion
- Dec 31, 2026
- Completion
- Apr 30, 2027
Study Design
- Enrollment
- 50 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- CROSSOVER
- Primary purpose
- OTHER
Arms
- Experimental: Product usage order BCNDHEGFSubjects will use each of the 8 products during an evaluation period, followed by a 4 hour Test Session.
- Experimental: Product usage order CDBENFHGSubjects will use each of the 8 products during an evaluation period, followed by a 4 hour Test Session.
- Experimental: Product usage order DECFBGNHSubjects will use each of the 8 products during an evaluation period, followed by a 4 hour Test Session.
- Experimental: Product usage order EFDGCHBNSubjects will use each of the 8 products during an evaluation period, followed by a 4 hour Test Session.
- Experimental: Product usage order FGEHDNCBSubjects will use each of the 8 products during an evaluation period, followed by a 4 hour Test Session.
- Experimental: Product usage order GHFNEBDCSubjects will use each of the 8 products during an evaluation period, followed by a 4 hour Test Session.
- Experimental: Product usage order HNGBFCEDSubjects will use each of the 8 products during an evaluation period, followed by a 4 hour Test Session.
- Experimental: Product usage order NBHCGDFESubjects will use each of the 8 products during an evaluation period, followed by a 4 hour Test Session.
Primary Outcome Measure
AUC nic 3-240 [ Time Frame: 3 minutes to 240 minutes ]
Central Contacts
- Emily Smith3367412396
- Kristen Prevette3364143176
Related Studies
- Antibiotic Prophylaxis in High-Risk Arthroplasty PatientsPHASE4 · Enrolling By Invitation · Mayo Clinic · Iowa City, Iowa
- Lung Macrophage Populations and Functions in Chronic Obstructive Pulmonary Disease (COPD)-Susceptible SmokersRecruiting · University of California, San Francisco · San Francisco, California
- RTMS Targets Neural Circuits for Smoking CessationRecruiting · Medical University of South Carolina · Charleston, South Carolina
- Smoke Free SafeCare: Establishing a Smoke Free Home in CPS-involved FamiliesRecruiting · Georgia State University · Atlanta, Georgia